Assertio Therapeutic ASRT 深 沪
等待开盘 12-31 09:30:00 美东时间
9.20
-0.330
-3.46%
华盛通- 最 高9.52
- 今 开9.52
- 成交量 13.18万股
- 最 低 8.86
- 昨 收 9.53
- 总市值 5903.46万
- 52周最高 15.15
- 市盈率 静 --
- 换手率 2.05%
- 52周最低 7.7055
- 委 比 92.34%
- 总股本 641.68万
- 历史最高 393.90
- 量 比 0.23
- 振 幅 6.93%
- 历史最低 7.7055
- 每 手 1
- 风险率 1.31%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Assertio Therapeutics Announces Leadership Change with CEO Resignation
The latest update is out from Assertio Therapeutics ( ($ASRT) ). On November 17...
11-22 06:32
Assertio Holdings shares are trading higher after the company reported better-than-expected Q3 financial results.
Assertio Holdings shares are trading higher after the company reported better-t...
11-11 05:20
Assertio Holdings Q3 Adj. EPS $0.18 Beats $(0.09) Estimate, Sales $49.459M Beat $27.020M Estimate
Assertio Holdings (NASDAQ:ASRT) reported quarterly earnings of $0.18 per share which beat the analyst consensus estimate of $(0.09) by 311.76 percent. This is a 800 percent increase over earnings of $0.02 per share from
11-11 05:14
Earnings Scheduled For November 10, 2025
Companies Reporting Before The Bell • CBAK Energy Tech (NASDAQ:CBAT) is likely ...
11-10 19:12
Earnings Outlook For Assertio Holdings
Assertio Holdings (NASDAQ:ASRT) is preparing to release its quarterly earnings ...
11-08 02:05
Assertio Appoints Mark L. Reisenauer As CEO, Effective Immediately, Succeeding Brendan P. O'Grady
Assertio Holdings, Inc. ("Assertio" or the "Company") (Nasdaq: ASRT), today announced that its Board of Directors (the "Board") has appointed director Mark L. Reisenauer as the Company's Chief Executive Officer ("CEO"),
10-28 21:16
Assertio Announces Leadership Transition
Assertio Holdings appointed Mark L. Reisenauer as CEO, effective immediately, succeeding Brendan P. O’Grady. Reisenauer, with over 30 years of experience in oncology and specialty products, is expected to lead the company's growth and efficiency. Assertio will report third-quarter 2025 results on November 10, 2025, and provide guidance updates. The company emphasized Reisenauer's expertise and stakeholder benefits from his leadership. A live webc...
10-28 13:15
Assertio Therapeutics Amends ROLVEDON Supply Agreement
Assertio Therapeutics ( ($ASRT) ) just unveiled an update. On October 7, 2025, ...
10-11 05:18
Assertio Presents First-Ever Real-World Study Showing Patient Experience with SYMPAZAN® (clobazam) Oral Film, CIV
Assertio announced new real-world data on SYMPAZAN (clobazam) Oral Film in treating Lennox-Gastaut Syndrome (LGS), a severe childhood epilepsy. Presented at the 150th American Neurological Association meeting, the study highlights SYMPAZAN's use in clinical practice, particularly for patients with swallowing difficulties. SYMPAZAN is the only FDA-approved oral film formulation for LGS seizures in patients aged two and older. The study analyzed 18...
09-15 13:00
Assertio Holdings Will Present New Data For Sympazan (Clobazam) At The Annual Meeting Of The American Neurological Association
Poster presentation will feature new data for SYMPAZAN, the only FDA-approved oral film formulation of clobazam for adjunctive treatment of seizures associated with Lennox-Gastaut syndrome in patients two years of age or
09-10 19:32
